Skip to main content

Table 3 Summary of all-causality adverse events occurring in >2 patients in the ITT population during the study period*

From: Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

Adverse event Cisplatin + gemcitabine + axitinib (n = 38)
All grades Grade ≥3
No. % No. %
Nausea 16 42.1   
Anaemia 12 31.6 3 7.9
Vomiting 11 28.9 2 5.3
Hypertension 10 26.3 5 13.2
Neutropaenia 9 23.7 5 13.2
Weight loss 9 23.7 0 0
Appetite loss 8 21.1 0 0
Fatigue 7 18.4 3 7.9
Asthenia 6 15.8 0 0
Leukopaenia 5 13.2 2 5.3
Diarrhoea 5 13.2 0 0
Reduced creatinine clearance 5 13.2 0 0
Alopecia 5 13.2 0 0
Thrombocytopaenia 4 10.5 0 0
Chest pain 4 10.5 0 0
Toxic nephropathy 4 10.5 0 0
Cough 4 10.5 0 0
Dyspnoea 4 10.5 0 0
Rash 4 10.5 0 0
Pulmonary cavitation 3 7.9 1 2.6
Haemoptysis 3 7.9 1 2.6
  1. ITT = intent-to-treat.
  2. *Study period comprised the treatment period plus 28-day follow-up period after the last dose of study drug.